- Home
- GECC vs AGEN Comparison
GECC vs AGEN Comparison
Compare GECC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GECC | AGEN |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.8M | 126.2M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | GECC | AGEN |
|---|---|---|
| Price | $6.80 | $3.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $10.75 | ★ $14.50 |
| AVG Volume (30 Days) | 116.0K | ★ 604.5K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 22.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $46,553,000.00 | ★ $106,829,000.00 |
| Revenue This Year | $32.16 | $67.15 |
| Revenue Next Year | $3.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.68 | N/A |
| 52 Week Low | $6.61 | $1.38 |
| 52 Week High | $11.46 | $7.34 |
Technical Indicators
Market Signals| Indicator | GECC | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 35.79 | 31.67 |
| Support Level | $6.61 | $3.26 |
| Resistance Level | $6.94 | $4.00 |
| Average True Range (ATR) | 0.27 | 0.25 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 12.50 | 30.49 |
Price Performance
Historical ComparisonAbout GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).